Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
optimized arenavirus vector
- Development stage
- Preclinical
- Lead developer
- Abalos Therapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
The **optimized arenavirus vector** is a genetically engineered, attenuated strain of lymphocytic choriomeningitis virus (LCMV), specifically WE-CL13 with mutations GP181M, GP185W, and GP492I in the glycoprotein, developed through serial passaging in tumor cells to enhance tumor tropism. It exhibits accelerated replication and propagation in various human tumor cells and organoids while showing limited replication in healthy cells, promoting strong, sustainable anti-tumor efficacy via T cell-mediated immunity without severe toxicity. Single intravenous administration demonstrates complete tumor remission in murine models of melanoma and other cancers, with safe tolerability in non-human primates, positioning it as a promising oncolytic virus-based immunotherapy.[1]
- Other names
- WE-CL13-GP181M-185W-492IWE-CL-13-GP181M-185W-492IWE-CL 13-GP181M-185W-492I
02
Targets
CD164LSECtin (Liver and lymph node sinusoidal endothelial cell C-type lectin)DC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))AXL (AXL receptor tyrosine kinase)TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)α-DG (Alpha-dystroglycan)
Beyond the preview
Go deeper on optimized arenavirus vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on optimized arenavirus vector.